WallStSmart
RVPH

Reviva Pharmaceuticals Holdings Inc.

NASDAQ: RVPH · HEALTHCARE · BIOTECHNOLOGY

$0.80
+3.19% today

Updated 2026-06-04

Market cap
$5.42M
P/E ratio
P/S ratio
EPS (TTM)
$-3.33
Dividend yield
52W range
$0 – $23
Volume
0.7M

WallStSmart proprietary scores

27
out of 100
Grade: F
Strong Sell
Investment rating
4.3
Growth
C
7.3
Quality
B+
3.0
Profitability
D
5.0
Valuation
C+
3/9
Piotroski F-Score
Weak
Altman Z-Score
Industry rank
View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target
$70.00
+8701.71%
12-Month target
Intrinsic (DCF)
Margin of safety
0 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Thin margins at 0.00%
- Negative free cash flow $-3.80M

Key financials

Revenue Net Income Free Cash Flow
Metric2022202320242025TTM
Revenue$0.00$0.00$0.00$0.00$0.00
Net income$-24.34M$-39.26M$-29.92M$-19.86M$-3.20M
EPS$-3.33
Free cash flow$-18.96M$-28.32M$-33.54M$-24.59M$-3.80M
Profit margin

Peer comparison

CompanyMkt CapScoreGrowthProfitValueQualityMoSRating
RVPH$5.42M274.33.05.07.3Avoid
LLY$948.95B7810.010.05.06.0Strong Buy
JNJ$536.54B594.79.03.36.0-71.41%Buy
ABBV$380.57B634.08.04.05.0-55.64%Buy
UNH$343.21B545.35.54.75.5-26.61%Buy
MRK$285.64B503.38.02.75.0-49.34%Hold

Smart narrative

Reviva Pharmaceuticals Holdings Inc. trades at $0.80. Our Smart Value Score of 27/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score.

Frequently asked questions

What is Reviva Pharmaceuticals Holdings Inc.'s stock price?

Reviva Pharmaceuticals Holdings Inc. (RVPH) trades at $0.80.

Is Reviva Pharmaceuticals Holdings Inc. overvalued?

Reviva Pharmaceuticals Holdings Inc. carries a Smart Value Score of 27/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Reviva Pharmaceuticals Holdings Inc. (RVPH)?

The 12-month analyst consensus target is $70.00, about 8701.7% above the current $0.80. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Company info

SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD

Quick metrics

P/S ratio
ROE-95.34%
Beta0.75
50D MA$0.80
200D MA$6.57
Shares out0.01B
Float0.01B
Short ratio
Avg volume0.7M

Performance

1 week
1 month
3 months
YTD
1 year
3 years
5 years